Y-Intercept (HK)’s LB Pharmaceuticals LBRX Stock Holding History

Y-Intercept (HK)’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.42M	Sell	37,076 -2,337	-6%	-$96.6K	0.03%	803
2026 Q2	$1.28M	Buy	+39,413	New	+$1.16M	0.03%	934

Other funds holding LBRX

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Y-Intercept (HK)'s LBRX Position: Q3 2026 in Review

Y-Intercept (HK) reduced its LB Pharmaceuticals (LBRX) stake by 5.9% in Q3 2026, selling an estimated $96.6K and leaving 37,076 shares worth $1.42M. The position accounts for 0.03% of the portfolio, ranked #803.

Y-Intercept (HK) first reported a position in LBRX in Q2 2026 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

Y-Intercept (HK) held 37,076 shares of LB Pharmaceuticals worth $1.42M as of Q3 2026.
Y-Intercept (HK) sold 2,337 LB Pharmaceuticals shares in Q3 2026, an estimated $96.6K.
LB Pharmaceuticals made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #803 holding.
Y-Intercept (HK) first reported a position in LB Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
8 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.